{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:44:14Z","timestamp":1774316654674,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Interferon\u2010\u03b1 is a cytokine that has demonstrated activity in patients with supratentorial gliomas, but its ideal dose and schedule of administration is unknown. Studies suggest that low\u2010dose, continuous exposure is more efficacious than intermittent, high doses. The authors performed a phase 2 study of recombinant interferon \u03b1\u20102b with monomethoxy polyethylene glycol (PEG\u2010Intron\u00ae) in children with diffuse intrinsic pontine glioma (DIPG), a population with dismal survival despite decades of clinical investigation. The primary objective was to compare 2\u2010year survival with a historic cohort that received radiation therapy alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients received weekly subcutaneous PEG\u2010Intron\u00ae at a dose of 0.3 \u03bcg\/kg beginning 2 to 10 weeks after the completion of radiation therapy until they developed disease progression. Patients were evaluated clinically and radiographically at regular intervals. Serum and urine were assayed for biomarkers before each cycle. Quality\u2010of\u2010life (QOL) evaluations were administered at baseline and before every other cycle of therapy to the parents of patients ages 6 to 18 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Thirty\u2010two patients (median age, 5.3 years; range, 1.8\u201014.8 years) were enrolled and received a median of 7 cycles of therapy (range, from 1 cycle to \u226570 cycles). PEG\u2010Intron\u00ae was well tolerated, and no decrease in QOL scores was noted in the subset of patients tested. The 2\u2010year survival rate was 14%, which was not significantly improved compared with the historic cohort. However, the median time to progression was 7.8 months, which compared favorably with recent trials reporting a time to progression of 5 months in a similar population.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Although low\u2010dose PEG\u2010Intron\u00ae therapy did not significantly improve 2\u2010year survival in children with DIPG compared with an historic control population, it did delay the time to progression. Cancer 2012;3607\u20133613. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26659","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T08:01:17Z","timestamp":1321430477000},"page":"3607-3613","source":"Crossref","is-referenced-by-count":45,"title":["A phase 2 study of pegylated interferon \u03b1\u20102b (PEG\u2010Intron\u00ae) in children with diffuse intrinsic pontine glioma"],"prefix":"10.1002","volume":"118","author":[{"given":"Katherine","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Bent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Camphausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70615-5"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq199"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq202"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq205"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1052"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2009.0067"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1985.63.5.0719"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01743290"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.783"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-T"},{"key":"e_1_2_6_13_2","first-page":"2726","article-title":"Interferon\u2010alpha mediated down regulation of angiogenesis\u2010related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule","volume":"5","author":"Slaton J","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-41631"},{"key":"e_1_2_6_15_2","first-page":"448","article-title":"Development of a quality of life scale for children with chronic illness with CNS involvement: preliminary data","volume":"6","author":"Wolters P","year":"2004","journal-title":"Neuro Oncol."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1989.70.5.0691"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.66.2.0227"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00572-5"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000121010"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.1080390216"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-9525(89)90007-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2260345"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(94)90058-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.003455"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08123.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.4.544"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.10.4562"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.06.020"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0644"},{"key":"e_1_2_6_30_2","first-page":"1395","article-title":"Increased incidence of matrix metalloproteinases in urine of cancer patients","volume":"58","author":"Moses M","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.022"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.5.356"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9143-x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2000.92.2.0255"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26659","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:52:37Z","timestamp":1760280757000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":33,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,7,15]]}},"alternative-id":["10.1002\/cncr.26659"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26659","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]}}}